INM Valuation

InMed Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.650

+0.02(0.760%)1D

Overview
Forecast
Valuation
Earnings

INM Relative Valuation

INM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INM is overvalued; if below, it's undervalued.

Historical Valuation

InMed Pharmaceuticals Inc (INM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.48 is considered Fairly compared with the five-year average of -1.06. The fair price of InMed Pharmaceuticals Inc (INM) is between 2.52 to 4.27 according to relative valuation methord.

Relative Value

Fair Zone

2.52-4.27

Current Price：2.69

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.45

P/B

Median3y

0.29

Median5y

1.17

-221.03

FCF Yield

Median3y

-305.07

Median5y

-203.48

Competitors Valuation Multiple

The average P/S ratio for INM's competitors is 0.92, providing a benchmark for relative valuation. InMed Pharmaceuticals Inc Corp (INM) exhibits a P/S ratio of 0.48, which is -48.47% above the industry average. Given its robust revenue growth of 7.59%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

INM.O

InMed Pharmaceuticals Inc

0.48

Average P/S: 0.92

7.59%